Compare Novo Nordisk A/S (NVO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Williams Companies Inc — how do they compare? Novo Nordisk A/S trades at $44.73 (market cap $200.69B), while Williams Companies Inc trades at $75.15 (market cap $92.75B). The key difference: Novo Nordisk A/S is far larger — about 2.2× Williams Companies Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | WMB | |
|---|---|---|
Market Cap | $200.69B | $92.75B |
Sector | Health | Energy |
52-Week High | $63.98 | $79.40 |
52-Week Low | $35.29 | $56.51 |
Enterprise Value | $215.49B | $123.38B |
Dividend Yield | 3.98% | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Williams Companies (WMB) trades at $75.83, up 2.27% with strong analyst support (79% buy ratings) and a $88.14 consensus target. The stock shows bullish technical momentum above key support at $74, supported by recent acquisitions and stable dividend payments. Fundamentals reveal robust profitability with 63.26% gross margins and 25.18% net income margin, though valuation multiples remain elevated with P/E at 30.21.
WMB offers exposure to growing natural gas infrastructure demand with recent $5.5 billion Momentum Midstream acquisition expanding Gulf Coast presence. Risks include regulatory challenges as seen with NJ pipeline permit reversal and elevated debt levels at 52% debt-to-asset ratio. The stock presents growth potential through LNG export expansion but faces execution risks on major projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
